A Risk Evaluation and Mitigation Strategy (REMS) is FDA's mechanism for ensuring that a drug's benefits outweigh its risks beyond what professional labeling alone can achieve. When a REMS includes Elements to Assure Safe Use (ETASU), it can restrict prescribing to certified providers, dispensing to certified pharmacies, and administration to certified healthcare settings. These restrictions exist for patient safety, but when the distribution design is poorly calibrated, the REMS becomes a bottleneck that delays or denies access to the patients who need the drug.
This article is for manufacturer access teams, hub-services leads, REMS administrators, and specialty pharmacy directors who need to understand where REMS distribution design breaks down and what to do about it.
REMS distribution architecture
REMS elements and their distribution impact
Under Section 505-1 of the FD&C Act, FDA can require one or more REMS elements. The distribution-relevant elements are:
| REMS element | Distribution impact | Burden level |
|---|---|---|
| Medication Guide | Dispensed with every prescription; minimal distribution impact | Low |
| Communication Plan | Letters to prescribers; no distribution restriction | Low |
| Elements to Assure Safe Use (ETASU) | Certification requirements for prescribers, pharmacies, or settings; limited distribution; patient enrollment | High |
| Implementation System | Monitoring and evaluation infrastructure; REMS-specific websites and call centers | High |
ETASU can require that a drug be dispensed only by certified pharmacies, only in certified healthcare settings, or only to patients enrolled in a registry. As of 2017, nearly 60% of active REMS programs included ETASU, up from approximately 25% in 2009, and the proportion has continued to grow as most newly approved REMS programs from 2021 through 2024 required ETASU.
Limited distribution networks
Many REMS drugs are distributed through limited distribution networks (LDDNs), where the manufacturer restricts dispensing to a small number of specialty pharmacies that meet REMS certification requirements. In an LDDN, the manufacturer selects pharmacies based on clinical expertise, REMS compliance infrastructure, cold-chain capability, patient support services, and data reporting.
The consequence: if a provider or health system is not affiliated with one of the authorized specialty pharmacies, they cannot obtain the drug. Integrated delivery networks (IDNs) and health system pharmacies that have the clinical expertise to manage the therapy may be excluded from the distribution network, forcing them to refer patients to an external pharmacy with potentially suboptimal geographic proximity and care coordination.
Shared system REMS for generic entry
When a branded drug with ETASU faces generic competition, FDA requires all applicants (brand and generic) to operate under a single shared system REMS. FDA facilitates the formation of an industry working group to negotiate distribution terms. Disagreements between brand and generic sponsors over distribution design, pharmacy networks, and cost allocation can delay generic entry.
Where the bottleneck forms
The specialty-pharmacy workflow gap
The specialty pharmacy is the last checkpoint before a REMS drug reaches the patient. Current REMS workflows at pharmacies are manual and fragmented:
- Pharmacy staff exit their existing workflow to log into external REMS portals
- Each REMS program requires a unique login, separate from the pharmacy management system
- Staff manually verify prescriber enrollment and patient enrollment status
- Staff generate a REMS Dispense Authorization (RDA)
- Staff separately report the dispense back to the REMS administrator
These manual steps introduce multiple failure points: transcription errors from manual data entry, missed verification steps from human oversight, and delays in RDA generation that slow prescription fulfillment. A 2015 NCPDP summit presentation documented that one-third of REMS orders were delayed by seven or more days due to patient sign-off requirements alone, and the overall time from prescription to dispensing for specialty drugs averaged three to six weeks.
Prescriber certification burden
REMS with ETASU often require prescribers to complete training, enroll in the REMS program, and agree to specific monitoring activities before they can prescribe the drug. The administrative burden discourages prescriber participation, particularly in community and rural settings. FDA acknowledges this concern and has statutory authority to require manufacturers to modify the REMS to minimize burden on the healthcare delivery system, but the modification process itself takes time.
Patient enrollment friction
ETASU may require that patients be enrolled in a registry, sign a patient-prescriber agreement, or undergo baseline testing (such as a negative pregnancy test) before the drug can be dispensed. Each enrollment step adds a checkpoint. If the enrollment process is paper-based, requires original signatures, or involves multiple stakeholders (prescriber, pharmacy, REMS administrator, patient), the cycle time extends. Patients in rural or medically underserved areas are disproportionately affected.
Technology fragmentation
As of 2026, REMS technology remains fragmented across multiple vendor platforms. The Duke-Margolis Center for Health Policy has documented the challenges of building a Common REMS Platform, and industry efforts such as UBC's RAPID API (built on the NCPDP SCRIPT standard) aim to automate REMS tasks directly within pharmacy workflows. But adoption is not yet universal. Many REMS programs still operate through standalone web portals that require manual data entry and do not integrate with electronic health records or pharmacy management systems.
Quantifying the access impact
Delay metrics from the field
- Average specialty drug time-to-therapy: three to six weeks from prescription to dispensing
- REMS-specific delays: one-third of orders delayed seven or more days by patient sign-off alone
- Clinic staff time: a median of 2 hours per prescription spent facilitating patient access for specialty drugs, with the pharmacy process alone taking a median of 6 days and accounting for more than half the time between prescription generation and medication access
- Prescriber certification dropout: programs with complex certification requirements see lower prescriber uptake
- Health system exclusion: IDNs with in-house specialty pharmacies may be unable to dispense REMS drugs if not included in the limited distribution network
The cost of non-compliance
When REMS requirements are not met, the drug cannot be dispensed. This creates a compliance vs. access tension: stricter REMS requirements improve safety monitoring but reduce the number of pharmacies and prescribers who participate, narrowing the access funnel. FDA's guidance on REMS design instructs sponsors to consider "how patients for whom the drug is indicated currently access health care (such as whether patients are in rural or medically underserved areas) and whether the REMS may disproportionately burden these populations."
Designing REMS distribution to minimize bottleneck risk
Distribution network sizing
The manufacturer must balance three competing objectives:
- Safety control: A narrow network ensures that only pharmacies with demonstrated REMS compliance infrastructure dispense the drug.
- Access breadth: A wider network ensures that patients can obtain the drug regardless of geography, health system affiliation, or payer arrangement.
- Operational efficiency: The network must be manageable from a manufacturer oversight perspective.
A practical framework for sizing the distribution network:
| Drug characteristic | Network approach | Rationale |
|---|---|---|
| Small patient population, high risk, complex monitoring | Limited distribution (3-5 specialty pharmacies) | Tight control is essential; patient volume supports dedicated coordination |
| Medium patient population, moderate ETASU complexity | Moderated limited distribution (8-15 pharmacies) | Balance control and access; include health system pharmacies with REMS capability |
| Large patient population, medication guide + communication plan only | Open distribution | Minimal ETASU burden; no need to restrict pharmacy network |
Technology integration requirements
REMS distribution design should specify technology integration expectations for network pharmacies:
- Electronic RDA generation through pharmacy management system integration (not manual web portal)
- Automated dispense reporting via NCPDP SCRIPT standard or equivalent
- Real-time prescriber and patient enrollment verification
- Adverse event reporting integrated into the pharmacy workflow
The NCPDP Foundation, FDA, and industry partners are working to promote REMS pharmacy technology integration through standardized network exchange. Sponsors should design REMS programs to be compatible with these emerging standards.
Exception and escalation pathways
The distribution design must include clear exception pathways for:
- Patients who cannot access an in-network specialty pharmacy due to geography or payer restrictions
- Health system pharmacies that meet or exceed REMS requirements but are not in the limited distribution network
- Prescribers who cannot complete certification due to legitimate barriers (e.g., lack of access to required training)
- Emergency or urgent-access situations where normal REMS enrollment would cause clinically unacceptable delay
FDA's guidance states that REMS programs should be "compatible with established medical drug distribution, procurement, and dispensing systems." If the REMS design forces a fundamental change in how patients access the drug, the design needs revision.
Manufacturer monitoring checklist
| Monitoring point | What to track | Threshold for intervention |
|---|---|---|
| Time to therapy | Days from prescription to first dispense | Median exceeds 21 calendar days |
| RDA rejection rate | Percentage of RDAs rejected for compliance gaps | Exceeds 5% of submissions |
| Prescriber certification completion | Percentage of targeted prescribers enrolled and certified | Below 60% within 6 months of launch |
| Patient enrollment completion | Percentage of prescribed patients enrolled in REMS | Below 70% within 30 days of prescription |
| Pharmacy network coverage | Geographic distribution of certified pharmacies | Any state with fewer than 2 certified pharmacies |
| Exception request volume | Number and type of exception requests received | Increasing trend over two consecutive quarters |
| Adverse event reporting timeliness | Days from event to REMS report | Exceeds FDA-specified timeline |
What to monitor next
- FDA's ongoing Common REMS Platform initiative and the potential for standardized, technology-enabled REMS administration
- NCPDP SCRIPT standard adoption for REMS pharmacy integration
- Shared system REMS negotiations for biosimilar and generic entry, which can expand or further restrict distribution networks
- State-level REMS-related legislation affecting pharmacy practice and distribution requirements
- FDA's assessment schedule for existing REMS programs (typically 18 months, 3 years, and 7 years post-approval) as opportunities to propose distribution modifications
Sources
- FDA. Risk Evaluation and Mitigation Strategies (REMS). fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems
- FDA. What's in a REMS? fda.gov/drugs/risk-evaluation-and-mitigation-strategies-rems/whats-rems
- FDA. Roles of Different Participants in REMS. fda.gov/drugs/risk-evaluation-and-mitigation-strategies-rems/roles-different-participants-rems
- FDA. FDA's Application of Statutory Factors in Determining When a REMS Is Necessary. Guidance for Industry. fda.gov/media/100307/download
- Section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1).
- Duke-Margolis Center for Health Policy. Improving the Development and Implementation of Shared System REMS. Workshop Summary. October 2020. healthpolicy.duke.edu
- Duke-Margolis Center for Health Policy. Building a Common REMS Platform. June 2016. healthpolicy.duke.edu
- Syneos Health. From Burden to Breakthrough: Leveraging Technology to Reduce Pharmacy REMS Stakeholder Burden. syneoshealth.com/insights-hub
- UBC. Optimizing REMS Pharmacy Integration: RAPID. ubc.com/insights
- Matrix Global Advisors. REMS and Restricted Distribution Programs. June 2017. getmga.com
- Kaiser Permanente Institute for Health Policy. Recommendations for Strengthening the FDA's REMS Program to Protect Patients. kpihp.org
- NCPDP Foundation. Data on specialty prescribing bottlenecks presented at 2015 Educational Summit. pocp.com
